Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
Amneal Reports Second Quarter 2024 Financial Results
As multiple drugmakers race to bring novel, levodopa-based Parkinson’s disease treatments to the market, New Jersey’s Amneal has taken home the gold in the U.S.
Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
Amneal to Report Second Quarter 2024 Results on August 9, 2024
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
Amneal Releases 2023 Environmental, Social and Governance Report
Teva Pharmaceuticals Industries Ltd.‘s patents for its ProAir HFA asthma inhaler must be stricken from the US Food and Drug Administration’s Orange Book, where they are listed among patents that protect name-brand drugs from generic competitors, a New Jersey federal judge ruled.